OQROSign up free
Insider trade

Regeneron Pharmaceuticals (REGN): Director sold ~$211K

Christine A Poon, Director at Regeneron Pharmaceuticals, sold ~$211K of Regeneron Pharmaceuticals shares.

~$211K
Approx. value · 218 sh @ $966.74
13K
Holds after · shares reported
Traded
Nov 2, 2026
Filed
Nov 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 2, 2026Insider · 2 peopleInsiders: 2 sales (~$1.4M)
  2. Sep 3, 2026InsiderOfficer sold ~$970K of REGN shares in the open market
  3. Sep 23, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Hopkinson v. Regeneron Pharmaceuticals, Inc.
  4. Sep 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated…”
  5. Oct 1, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
  6. Oct 1, 2026Government · Federal Register noticeAdvisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal
  7. Oct 14, 2026Insider · 1 personInsiders: 27 sales (~$3.2M)
  8. Oct 30, 2026Company filing · Form 8-K · ResultsReported its results
  9. Oct 30, 2026Insider · 3 peopleInsiders: 3 sales (~$3.0M)
  10. Nov 2, 2026 · this disclosureInsiderDirector sold ~$211K of REGN shares in the open market

What came next

  1. Nov 2, 2026Insider · 3 peopleInsiders: 16 sales (~$32.1M)
  2. Nov 3, 2026Insider · 1 personInsiders: 2 sales (~$7.2M)
  3. Nov 4, 2026Insider · 1 personInsiders: 8 sales (~$3.8M)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 73 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Christine A Poon, Director

The full history of Christine A Poon, Director is on the profile page.

How this filing works

Explore the data

Other disclosures at Regeneron Pharmaceuticals

Everything OQRO holds on this company is on its REGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data